Nirsevimab Library
This is a collection of current resources related to Nirsevimab.
Respiratory Syncytial Virus (RSV): Advisory Committee on Immunization Practices (ACIP) Recommendations
2024
· Johns Hopkins University
The Advisory Committee on Immunization Practices (ACIP) provides guidelines for preventing Respiratory Syncytial Virus (RSV). Infants up to 8 months should get a dose of …
Ask aRCie
Estimates: Nirsevimab 89% Effective Against RSV in Kids, 93% Against Hospitalization
2024
· University of Minnesota
This news brief describes the effectiveness of nirsevimab, a monoclonal antibody drug, in protecting children under 5 from RSV. The drug is 89% effective against …
Studies Show More Promising Results for RSV Drug Nirsevimab
2024
· University of Minnesota
This blog post describes two studies showing that the RSV drug nirsevimab is effective in protecting infants from respiratory syncytial virus. The first study found …
Respiratory Syncytial Virus Vaccine and Nirsevimab Uptake Among Pregnant People and Their Neonates
This study was conducted to describe the uptake of the prenatal RSVpreF vaccine and infant nirsevimab during the 2023-2024 RSV season. It found high uptake …
Maternal RSVpreF and Infant Nirsevimab Immunizations Uptake During Respiratory Syncytial Virus Season
This research letter looks at a study that analyzed the uptake of RSVpreF vaccination during pregnancy and nirsevimab administration to infants during the 2023 to …
New and Emerging Passive Immunization Strategies for the Prevention of RSV Infection During Infancy
This article discusses new ways to protect babies from RSV, a virus causing lung infections. Two methods were approved in 2023: one uses a long-lasting …
RSV Prevention Update: ACIP/AAP Recommendations for Nirsevimab in Infants and RSV Vaccine in Pregnancy
These presentation slides provide information for physicians about recommendations for nirsevimab for prevention of serious lower respiratory tract infection from respiratory syncytial virus (RSV) in …
Uptake of Maternal RSV Vaccination and Infant Nirsevimab Among Infants Born October 2023 to March 2024
2025
· Kaiser Permanente
The article investigates the uptake of maternal RSV vaccination and infant nirsevimab among infants born from October 2023 to March 2024 within Kaiser Permanente Northern …
Efficacy of Nirsevimab Against Respiratory Syncytial Virus Lower Respiratory Tract Infections in Preterm and Term Infants, and Pharmacokinetic Extrapolation to Infants With Congenital Heart Disease and Chronic Lung Disease: A Pooled Analysis of Randomised Controlled Trials
2023
· Children's Hospital Colorado,
· University of the Witwatersrand,
· Northwestern University,
· Dr. Georgi Stranski University Hospital,
· Quironsalud Madrid University Hospital,
· State University of New York - Upstate Medical University
This article describes a study on the effectiveness of nirsevimab in preventing respiratory syncytial virus (RSV) infections in infants. It focuses on both preterm and …
Review and Update of Active and Passive Immunization Against Respiratory Syncytial Virus
This article reviews ways to protect against respiratory syncytial virus (RSV). It describes both active and passive immunization methods. Active immunization involves vaccines that help …